Anxiolytic

Oyster Point Pharma to Present New Scientific Analyses at World Cornea Congress VIII

Retrieved on: 
Tuesday, September 27, 2022
Safety, Rest, Menopause, P, User experience, Sneeze, U.S. Securities and Exchange Commission, Stinger, Nasdaq, Pharmacy, Nasal spray, Research, Risk, COVID-19, Prevalence, Homeostasis, Parasympathetic nervous system, Antibody, Company, Detail, Nach, Treatment, Cornea, Trigeminal nerve, Science, Insurance, Lipid, Patent, IgG4-related ophthalmic disease, FACS, Tax Cuts and Jobs Act of 2017, Throat irritation, Tears, FDA, Duane syndrome, NK, Ophthalmology, Security (finance), GLOBE, Congress, Anxiolytic, Cough, Dry eye syndrome, Jumpstart Our Business Startups Act, LinkedIn, Private Securities Litigation Reform Act, Nose, Eye, Protein, Scratching, INT, Pharmaceutical industry, Varenicline, Signs and symptoms, MD, Patient

PRINCETON, N.J., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), (Oyster Point Pharma, or the Company), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases, today announced it will present new scientific analyses at World Cornea Congress VIII, which is taking place in Chicago, Illinois from September 28-29, 2022.

Key Points: 
  • PRINCETON, N.J., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), (Oyster Point Pharma, or the Company), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases, today announced it will present new scientific analyses at World Cornea Congress VIII, which is taking place in Chicago, Illinois from September 28-29, 2022.
  • We are excited to share the results of our study at World Cornea Congress.
  • I am encouraged by the results of our research and look forward to presenting this featured paper presentation at World Cornea Congress.
  • In October 2021, Oyster Point Pharma received FDA-approval for TYRVAYA (varenicline solution) Nasal Spray for the treatment of the signs and symptoms of dry eye disease.

BetterLife-Carleton University Research Team Secure Mitacs Accelerate Funding to Study the Therapeutic Effect of TD-010 in Chronic Anxiety

Retrieved on: 
Thursday, July 22, 2021
Psychoactive drugs, GABAA receptor positive allosteric modulators, Hypnotics, Muscle relaxants, Sedatives, Anxiolytic, Neurochemistry, Benzodiazepine

TD-010 or dihydrohonokiol-B (DHH-B) is a compound that BetterLife is developing primarily for benzodiazepine dependency in addition to anxiety.

Key Points: 
  • TD-010 or dihydrohonokiol-B (DHH-B) is a compound that BetterLife is developing primarily for benzodiazepine dependency in addition to anxiety.
  • We thank Mitacs for the funding and Carleton Universitys team, headed by Dr. Argel Aguilar-Valles at the Department of Neuroscience, for being an ideal partner to help us realize this vision."
  • The high rate of resistance to benzodiazepine and SSRIs for chronic anxiety disorder indicates an urgent unmet need for alternative anxiolytic treatments.
  • Mitacs is a not-for-profit organization that fosters growth and innovation in Canada by solving business challenges with research solutions from academic institutions.

Survey Reveals Prescription Use Among Insomnia Patients Tied to Comorbidities, Severity, HCP Engagement

Retrieved on: 
Monday, November 23, 2020
Mind, Branches of biology, Psychiatric diagnosis, Sleep disorders, Insomnia, Psychoactive drugs, Antidepressant, Depressant, Anxiolytic, Sleep, Hypnotic, Cognitive behavioral therapy for insomnia

Of the respondents within the Sleep Disorders In America survey who answered insomnia-specific questions, more than six in 10 said they currently take a prescription medication that treats insomnia or related symptoms.

Key Points: 
  • Of the respondents within the Sleep Disorders In America survey who answered insomnia-specific questions, more than six in 10 said they currently take a prescription medication that treats insomnia or related symptoms.
  • These prescriptions include those specifically approved for treating insomnia, as well as medications that promote wakefulness, stimulants, pain relievers and anti-anxiety or antidepressant medications.
  • Similarly, respondents with insomnia who don't currently take a prescription were more likely to consider their condition severity to be mild.
  • The findings suggest that respondents who currently use prescription medications are simultaneously dealing with other medical conditions in addition to their insomnia.

Artelo Biosciences Files Patent on Use of Fatty Acid Binding Protein 5 Inhibitors for Treating Psychological Disorders

Retrieved on: 
Wednesday, October 21, 2020
Psychiatric diagnosis, RTT, Psychiatry, Branches of biology, Psychoactive drugs, Abnormal psychology, TAAR1 agonists, Anxiety disorders, Post-traumatic stress disorder, Anxiolytic, Anxiety, Serotonin

Anxiety disorders, such as PTSD, and chronic stress are currently treated using interventional therapeutic approaches and medications such as those that affect serotonin and/or norepinephrine.

Key Points: 
  • Anxiety disorders, such as PTSD, and chronic stress are currently treated using interventional therapeutic approaches and medications such as those that affect serotonin and/or norepinephrine.
  • However, commonly prescribed anti-anxiety drugs have been linked to serious side-effects, including drug dependence and withdrawal, cognitive impairments and metabolic symptoms.
  • These new data suggest FABP5 inhibition may provide a novel approach to treating certain psychological disorders with less deleterious impact than experienced with current methodologies.
  • Already known to have potential for treating cancer, inflammation, and pain, FABP5 inhibitors may also have an important role in the management of anxiety disorders including PTSD.

Seelos Announces Issuance of a New Patent and an Additional Notice of Allowance in Japan for Intranasal Racemic Ketamine (SLS-002)

Retrieved on: 
Monday, September 14, 2020
Phobias, Psychiatry, RTT, Anxiety disorders, Psychiatric diagnosis, Abnormal psychology, Social anxiety disorder, Agoraphobia, Specific phobia, Anxiolytic, Patent

NEW YORK, Sept. 14, 2020 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, announced today that it has received an issued patent from the Japanese Patent Office (Japanese patent number 6722453) covering SLS-002 titled: ANXIOLYTIC COMPOSITION, FORMULATION AND METHOD OF USE.

Key Points: 
  • NEW YORK, Sept. 14, 2020 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, announced today that it has received an issued patent from the Japanese Patent Office (Japanese patent number 6722453) covering SLS-002 titled: ANXIOLYTIC COMPOSITION, FORMULATION AND METHOD OF USE.
  • The issued claims cover a formulation and method of using SLS-002 to treat patients experiencing anxiety due to phobic disorders such as: Specific Phobia, Agoraphobia, and Social Phobia.
  • Additionally, Seelos has received a Notice of Allowance from the Japanese Patent Office (Japanese patent application number 2018-124196) covering SLS-002 titled: ANXIOLYTIC COMPOSITION, FORMULATION AND METHOD OF USE.
  • The allowed claims cover a formulation and method of using SLS-002 to prevent anxiety in patients prior to medical or dental procedures.

Social Anxiety Disorder Market Analysis 2020 - Pipeline, Epidemiology, Market Valuations, Drug Sales, Market Forecasts, Drug Forecasts and Market Shares - ResearchAndMarkets.com

Retrieved on: 
Tuesday, June 23, 2020
Mental health, Health, Psychiatry, Anxiety disorders, RTT, Psychology, Psychiatric diagnosis, Medical diagnosis, Phobias, Abnormal psychology, Social anxiety disorder, Anxiety, Social anxiety, Anxiolytic

The "Global Social Anxiety Disorder Market and Competitive Landscape - 2020" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Social Anxiety Disorder Market and Competitive Landscape - 2020" report has been added to ResearchAndMarkets.com's offering.
  • This report provides comprehensive insights into the Social Anxiety Disorder pipeline, epidemiology, market valuations, drug sales, market forecast, drug forecasts, and market shares.
  • This research analyzes and forecasts the Social Anxiety Disorder market size and drug sales.
  • Social Anxiety Disorder pipeline: Find out drugs in clinical trials for the treatment of Social Anxiety Disorder by development phase 3, phase 2, and phase 1, by pharmacological class and company
    Social Anxiety Disorder drugs: Identify key drugs marketed and prescribed for Social Anxiety Disorder in the US, including trade name, molecule name, and company
    Social Anxiety Disorder drugs sales: Find out the sales value for Social Anxiety Disorder drugs by countries
    Social Anxiety Disorder market valuations: Find out the market size for Social Anxiety Disorder drugs in 2019 by countries.

Global Social Anxiety Disorder Market 2020 - Epidemiology Analysis by Country

Retrieved on: 
Monday, June 8, 2020
Psychiatry, Anxiety disorders, Psychiatric diagnosis, Psychology, Human behavior, RTT, Abnormal psychology, Social anxiety disorder, Anxiety, Social anxiety, Generalized anxiety disorder, Anxiolytic

DUBLIN, June 8, 2020 /PRNewswire/ -- The "Global Social Anxiety Disorder Market and Competitive Landscape - 2020" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, June 8, 2020 /PRNewswire/ -- The "Global Social Anxiety Disorder Market and Competitive Landscape - 2020" report has been added to ResearchAndMarkets.com's offering.
  • This report provides comprehensive insights into the Social Anxiety Disorder pipeline, epidemiology, market valuations, drug sales, market forecast, drug forecasts, and market shares.
  • This research covers the following: Social Anxiety Disorder treatment options, Social Anxiety Disorder late stage clinical trials pipeline, Social Anxiety Disorder prevalence by countries, Social Anxiety Disorder market size and forecast by countries, key market events and trends, drug sales and forecast by countries, and market shares by countries.
  • Social Anxiety Disorder pipeline: Find out drugs in clinical trials for the treatment of Social Anxiety Disorder by development phase 3, phase 2, and phase 1, by pharmacological class and company
    Social Anxiety Disorder drugs: Identify key drugs marketed and prescribed for Social Anxiety Disorder in the US, including trade name, molecule name, and company
    Social Anxiety Disorder drugs sales: Find out the sales value for Social Anxiety Disorder drugs by countries
    Social Anxiety Disorder market valuations: Find out the market size for Social Anxiety Disorder drugs in 2019 by countries.

Ganaxolone Drug Overview and Outlook 2020-2030

Retrieved on: 
Thursday, April 30, 2020
Psychoactive drugs, Drugs, GABAA receptor positive allosteric modulators, Neurochemistry, Sedatives, RTT, Ketones, Pregnanes, Ganaxolone, Benzodiazepine, Postpartum depression, Anxiolytic

Marinus Pharmaceuticals is developing Ganaxolone in phase II stage of development for the treatment of Postpartum Depression.

Key Points: 
  • Marinus Pharmaceuticals is developing Ganaxolone in phase II stage of development for the treatment of Postpartum Depression.
  • Unlike benzodiazepines, ganaxolone exhibits anti-seizure and anti-anxiety activity via its effects on synaptic and extra-synaptic GABAA receptors.
  • The report provides insights into:
    A comprehensive product overview including the product description, mechanism of action, dosage and administration, Research and Development activity.
  • What are the other emerging products available and how these are giving competition to Ganaxolone?

Antianxiety and Antidepressant Effects from a Single Dose of Psychedelic Drug Persist Years Later in Cancer Patients

Retrieved on: 
Tuesday, January 28, 2020
Articles, Health, Depression, Psychiatric diagnosis, Antidepressant, Anxiolytic, Major depressive disorder, Psycho-Oncology, Terminal illness, Hospice

At the final 6.5-month follow-up assessment, psilocybin was associated with enduring antianxiety and antidepressant effects.

Key Points: 
  • At the final 6.5-month follow-up assessment, psilocybin was associated with enduring antianxiety and antidepressant effects.
  • The study reports on sustained reductions in anxiety, depression, hopelessness, demoralization, and death anxiety at both follow-up points.
  • Approximately 60 percent to 80 percent of participants met criteria for clinically significant antidepressant or anxiolytic responses at the 4.5 year follow-up.
  • "This could profoundly transform the psycho-oncologic care of patients with cancer, and importantly could be used in hospice settings to help terminally ill cancer patients approach death with improved emotional and spiritual well-being," says Ross.

Global Antidepressant and Anti-Anxiety Drugs Market 2019-2029

Retrieved on: 
Thursday, June 6, 2019
Selective serotonin reuptake inhibitors, Depression, Psychiatry, Psychiatric diagnosis, Anxiolytic, RTT, Chemical compounds, Antidepressants, Anxiety disorders

In 2018, the SSRIs segment held 26% of the global antidepressant and anti-anxiety drugs market.

Key Points: 
  • In 2018, the SSRIs segment held 26% of the global antidepressant and anti-anxiety drugs market.
  • Read on to discover how you can exploit the future business opportunities emerging in this sector.
  • In this brand new 213-page report you will receive 73 tables and 92 figures all unavailable elsewhere.
  • The 213-page report provides clear detailed insight into the global antidepressant and anti-anxiety drugs market.